Clindamycin seems to be being used more frequently (just an anecdotal observation). The Archivist has always held clindamycin in reserve for careful use as an adjuvant to using β-lactam antibiotics for the more severe group A β-haemolytic streptococcal invasive infections (iGAS) such as necrotising fasciitis. Is there good evidence of a benefit in the use of clindamycin in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections? Babiker A et al. [Lancet Infectious Dis 2021 https://doi.org/10.1016/ S1473-3099(20)30523-5] have published the findings of a retrospective multicentre cohort study, using a dataset from adult patients in an …